[1]王静,李汉超,莫凌菲,等.RSAD2 mRNA表达对贝利尤单抗治疗系统性红斑狼疮应答的预测价值[J].陕西医学杂志,2025,54(6):804-808,834.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.016]
　WANG Jing,LI Hanchao,MO Lingfei,et al.Predictive value of RSAD2 mRNA expression for belimumab treatment response in SLE patients[J].,2025,54(6):804-808,834.[doi:DOI:10.3969/j.issn.1000-7377.2025.06.016]
点击复制

RSAD2 mRNA表达对贝利尤单抗治疗系统性红斑狼疮应答的预测价值

《陕西医学杂志》[ISSN:1000-7377/CN:61-1281/TN]

卷:
54
期数:
2025年6期
页码:
804-808,834
栏目:
药物与临床
出版日期:
2025-06-05

文章信息/Info

Title:
Predictive value of RSAD2 mRNA expression for belimumab treatment response in SLE patients
作者:
王静; 李汉超; 莫凌菲; 张妮; 刘新毅; 冯秀媛; 王沛; 李园园
（西安交通大学第一附属医院风湿免疫科，陕西 西安 710061）
Author(s):
WANG Jing; LI Hanchao; MO Lingfei; ZHANG Ni; LIU Xinyi; FENG Xiuyuan; WANG Pei; LI Yuanyuan
(Department of Rheumatology and Immunology,the First Affiliated Hospital of Xi’an Jiaotong University,Xi’an 710061,China)
关键词:
系统性红斑狼疮; S-腺苷蛋氨酸结构域蛋白2; 贝利尤单抗; 疾病活动度; 预测价值
Keywords:
Systemic lupus erythematosus; RSAD2; Belimumab; Disease activity; Predictive value
分类号:
R 593.24
DOI:
DOI:10.3969/j.issn.1000-7377.2025.06.016
文献标志码:
A
摘要:
目的：探讨S-腺苷蛋氨酸结构域蛋白2（RSAD2）mRNA在系统性红斑狼疮（SLE）患者外周血单个核细胞（PBMCs）中的表达及其对贝利尤单抗治疗应答的预测价值。方法：将接受贝利尤单抗治疗的48例SLE患者纳入SLE组，将年龄、性别匹配的健康女性48例纳入健康对照组，比较两组PBMCs中RSAD2 mRNA表达水平，以及治疗前后SLE组生化指标[白细胞计数（WBC）、血小板计数（PLT）、C-反应蛋白（CRP）、血沉（ESR）、白蛋白（ALB）、24 h尿蛋白（24 hUP）]、免疫学指标[抗dsDNA抗体、IgG、补体C3、补体C4]和系统性红斑狼疮疾病活动指数2000（SLEDAI-2K）评分，分析治疗前RSAD2 mRNA表达水平对预测贝利尤单抗治疗应答的价值。结果：与治疗前比较，SLE患者在接受贝利尤单抗治疗3、6、12个月后生化指标（除WBC和PLT外）、免疫学指标及SLEDAI-2K评分等明显好转（均P<0.05）。SLE组治疗前RSAD2 mRNA表达较健康对照组明显升高，且其表达水平与SLEDAI-2K评分呈正相关（均P<0.05）。SLE组接受贝利尤单抗治疗12个月的狼疮反应指数4（SRI-4）应答率为75.00%，且应答患者治疗前RSAD2 mRNA表达高于未应答患者（P<0.01）。治疗前RSAD2 mRNA表达对贝利尤治疗第12个月时的应答具有一定的预测价值（P<0.01），敏感度为61.11%，特异度为83.33%。结论：RSAD2 mRNA在SLE患者外周血PBMCs中高表达，对SLE患者贝利尤单抗治疗应答具有良好的预测价值。
Abstract:
Objective:To investigate the expression of radical S-adenosyl methionine domain containing 2 (RSAD2) mRNA in peripheral blood mononuclear cells (PBMCs) of systemic lupus erythematosus (SLE) patients and its predictive value for the response to belimumab treatment.Methods：A total of 48 SLE patients treated with belimumab were included in the SLE group,and 48 healthy women matched for age and sex were included in the healthy control group.The expression level of RSAD2 mRNA in PBMCs between the two groups,and biochemical indicators (WBC,PLT,CRP,ESR,ALB,24 hUP) and immunological indexes [anti-dsDNA antibody,IgG,complement C3,complement C4] and SLEDAI-2K score in SLE group before and after treatment were compared.The value of RSAD2 mRNA expression level before treatment in predicting the treatment response of belimumab was analyzed.Results:Biochemical parameters (except WBC and PLT),immunological parameters and SLEDAI-2K scores were significantly improved after 3,6 and 12 months of belimumab treatment compared with pre-treatment (all P<0.05).The expression of RSAD2 mRNA in the SLE group was significantly higher than that in the healthy control group before treatment,and its expression level was positively correlated with SLEDAI-2K score (all P<0.05).The response rate of SRI-4 in SLE patients treated with belimumab for 12 months was 75.00%,and the expression of RSAD2 mRNA in responders was higher than that in non-responders before treatment (P<0.01).RSAD2 mRNA expression before treatment had a certain predictive value for the response to belimumab at month 12 (P<0.01),with a sensitivity of 61.11% and a specificity of 83.33%.Conclusion:RSAD2 mRNA is highly expressed in peripheral blood PBMCs of SLE patients and has a good predictive value for the response to belimumab in SLE patients.

参考文献/References:

[1]ARBITMAN L,FURIE R,VASHISTHA H.B cell-targeted therapies in systemic lupus erythematosus[J].J Autoimmun,2022,132：102873.
[2]KRUSTEV E,CLARKE A E,BARBER M R W.B cell depletion and inhibition in systemic lupus erythematosus[J].Expert Rev Clin Immunol,2023,19(1)：55-70.
[3]TAUBMANN J,MULLER F,YALCIN M M,et al.CD19 chimeric antigen receptor T cell treatment：Unraveling the role of B cells in systemic lupus erythematosus[J].Arthritis Rheumatol,2024,76(4)：497-504.
[4]SINGH J A,SHAH N P,MUDANO A S.Belimumab for systemic lupus erythematosus[J].Cochrane Database Syst Rev,2021,2(2)：CD010668.
[5]ZHANG F,BAE S C,BASS D,et al.A pivotal phase Ⅲ,randomised,placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China,Japan and South Korea[J].Ann Rheum Dis,2018,77(3)：355-363.
[6]NEUPANE B,SHUKLA P,SLIM M,et al.Belimumab versus anifrolumab in adults with systemic lupus erythematosus：An indirect comparison of clinical response at 52 weeks[J].Lupus Sci Med,2023,10(1)：e000907.
[7]MORAND E F,FURIE R,TANAKA Y,et al.Trial of anifrolumab in active systemic lupus erythematosus[J].N Engl J Med,2020,382(3)：211-221.
[8]WANG X,FU S,YU J,et al.Renal interferon-inducible protein 16 expression is associated with disease activity and prognosis in lupus nephritis[J].Arthritis Res Ther,2023,25(1)：112.
[9]SHEN M,DUAN C,XIE C,et al.Identification of key interferon-stimulated genes for indicating the condition of patients with systemic lupus erythematosus[J].Front Immunol,2022,13：962393.
[10]ARINGER M,COSTENBADER K,DAIKH D,et al.2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus[J].Ann Rheum Dis,2019,78(9)：1151-1159.
[11]URIBE A G,VIL L M,MCGWIN G,et al.The systemic lupus activity measure-revised,the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI),and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus[J].J Rheumatol,2004,31(10)：1934-1940.
[12]MOYSIDOU G S,GARANTZIOTIS P,SENTIS G,et al.Molecular basis for the disease-modifying effects of belimumab in systemic lupus erythematosus and molecular predictors of early response：Blood transcriptome analysis implicates the innate immunity and DNA damage response pathways[J].Ann Rheum Dis,2025,84(2)：262-273.
[13]BAO D,DRENKARD C,DUNLOP-THOMAS C,et al.Direct medical charges in a population-based systemic lupus erythematosus cohort[J].J Med Econ,2024,27(1)：982-990.
[14]高岱,张卓莉.达标治疗-系统性红斑狼疮疾病管理模式的一次飞跃[J].中华风湿病学杂志,2024,28(2)：73-77.
[15]朱德礼,李建平,张元丽,等.参芪地黄汤联合来氟米特治疗气阴两虚型狼疮性肾炎临床研究[J].陕西中医,2023,44(8)：1069-1073.
[16]李丽,蒋芙蓉,赵丽英,等.血清肿瘤坏死因子受体相关因子3和卵泡抑素样蛋白1检测对系统性红斑狼疮患者吗替麦考酚酯治疗无效的预测价值[J].陕西医学杂志,2024,53(9)：1254-1258.
[17]DONG C,GUO Y,CHEN Z,et al.Single-cell profiling of bone marrow B cells and early B cell developmental disorders associated with systemic lupus erythematosus[J].Arthritis Rheumatol,2024,76(4)：599-613.
[18]MCKEL T,BASTA F,WEINMANN-MENKE J,et al.B cell activating factor (BAFF)：Structure,functions,autoimmunity and clinical implications in systemic lupus erythematosus (SLE)[J].Autoimmun Rev，2021,20(2)：102736.
[19]陆爱玲,陆柯曲,肖媛元,等.贝利尤单抗治疗系统性红斑狼疮安全性和有效性-单中心真实世界研究[J].中华风湿病学杂志,2023,27(9)：580-588.
[20]POSTAL M,VIVALDO J F,FERNANDEZ-RUIZ R,et al.Type I interferon in the pathogenesis of systemic lupus erythematosus[J].Curr Opin Immunol,2020,67：87-94.
[21]SHI L Z,BONNER J A.Bridging radiotherapy to immunotherapy：The IFN-JAK-STAT axis[J].Int J Mol Sci,2021,22(22)：12295.
[22]VAN EYNDHOVEN L C,CHOURI E,MATOS C I,et al.Unraveling IFN-I response dynamics and TNF crosstalk in the pathophysiology of systemic lupus erythematosus[J].Front Immunol,2024,15：1322814.
[23]HOU L,WU Z,ZENG P,et al.RSAD2 suppresses viral replication by interacting with the senecavirus A2C protein[J].Vet Res,2024,55(1)：115.
[24]CECCHI I,RADIN M,BARINOTTI A,et al.Type I interferon pathway activation across the antiphospholipid syndrome spectrum：Associations with disease subsets and systemic antiphospholipid syndrome presentation[J].Front Immunol,2024,15：1351446.
[25]曲婧格,王也,李熙萌,等.系统性红斑狼疮患者外周血单个核细胞中RSAD2表达及意义[J].山东医药,2018,58(30)：3.

相似文献/References:

[1]李 赟.系统性红斑狼疮患者血清补体C5a和红细胞沉降率检测及临床意义[J].陕西医学杂志,2020,49(1):52.
　LI Yun..Expression of serum C5a and ESR in patients with systemic lupus erythematosus and its clinical significance[J].,2020,49(6):52.
[2]张彦平,贺军涛△,殷 鉴,等.尿液免疫球蛋白轻链检测对系统性红斑狼疮肾脏损伤的诊断价值*[J].陕西医学杂志,2020,49(9):1172.[doi:DOI:10.3969/j.issn.1000-7377.2020.09.030]
　ZHANG Yanping,HE Juntao,YIN Jian,et al.Diagnostic value of urine U-kap and U-lam detection in renalinjury of systemic lupus erythematosus[J].,2020,49(6):1172.[doi:DOI:10.3969/j.issn.1000-7377.2020.09.030]
[3]付永涛,王莉平,郭金明,等.羟氯喹通过Toll样受体4/核因子-κB信号通路对系统性红斑狼疮小鼠肺损伤的影响[J].陕西医学杂志,2023,52(11):1483.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.007]
　FU Yongtao,WANG Liping,GUO Jinming,et al.Effect of hydroxychloroquine on lung injury in mice with systemic lupus erythematosus via TLR4/NF-κB signaling pathway[J].,2023,52(6):1483.[doi:DOI:10.3969/j.issn.1000-7377.2023.11.007]
[4]王赓丰,崔家康,孟庆良.铁死亡在系统性红斑狼疮中的作用研究进展[J].陕西医学杂志,2024,(5):710.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.031]
　WANG Gengfeng,CUI Jiakang,MENG Qingliang.Research progress on the role of ferrosis in systemic lupus erythematosus[J].,2024,(6):710.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.031]
[5]李 丽,蒋芙蓉,赵丽英,等.血清肿瘤坏死因子受体相关因子3和卵泡抑素样蛋白1检测对系统性红斑狼疮患者吗替麦考酚酯治疗无效的预测价值[J].陕西医学杂志,2024,(9):1254.[doi:DOI:10.3969/j.issn.1000-7377.2024.09.022]
　LI Li,JIANG Furong,ZHAO Liying,et al.Predictive value of serum TRAF3 and FSTL1 levels in patients with systemic lupus erythematosus for failure to respond to mycophenolate mofetil treatment[J].,2024,(6):1254.[doi:DOI:10.3969/j.issn.1000-7377.2024.09.022]
[6]王玲玲,詹宇威,杨 舟.系统性红斑狼疮合并感染患者淋巴细胞亚群、PLR、NLR、MLR水平变化及检测意义[J].陕西医学杂志,2024,(11):1487.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.010]

备注/Memo

备注/Memo:
国家自然科学基金资助项目（82371811）；陕西省自然科学基础研究计划项目（2023-JC-YB-754）
更新日期/Last Update: 2025-06-04